Literature DB >> 24555916

Improved survival with an ambulatory model of non-invasive ventilation implementation in motor neuron disease.

Nicole Sheers1, David J Berlowitz, Linda Rautela, Ian Batchelder, Kim Hopkinson, Mark E Howard.   

Abstract

Non-invasive ventilation (NIV) increases survival and quality of life in motor neuron disease (MND). NIV implementation historically occurred during a multi-day inpatient admission at this institution; however, increased demand led to prolonged waiting times. The aim of this study was to evaluate the introduction of an ambulatory model of NIV implementation. A prospective cohort study was performed. Inclusion criteria were referral for NIV implementation six months pre- or post-commencement of the Day Admission model. This model involved a 4-h stay to commence ventilation with follow-up in-laboratory polysomnography titration and outpatient attendance. Outcome measures included waiting time, hospital length of stay, adverse events and polysomnography data. Results indicated that after changing to the Day Admission model the median waiting time fell from 30 to 13.5 days (p < 0.04) and adverse events declined (4/17 pre- (three deaths, one acute admission) vs. 0/12 post-). Survival was also prolonged (median (IQR) 278 (51-512) days pre- vs 580 (306-1355) days post-introduction of the Day Admission model; hazard ratio 0.41, p = 0.04). Daytime PaCO2 was no different. In conclusion, reduced waiting time to commence ventilation and improved survival were observed following introduction of an ambulatory model of NIV implementation in people with MND, with no change in the effectiveness of ventilation.

Entities:  

Keywords:  Non-invasive ventilation; ambulatory model of care; motor neuron disease; survival

Mesh:

Year:  2014        PMID: 24555916     DOI: 10.3109/21678421.2014.881376

Source DB:  PubMed          Journal:  Amyotroph Lateral Scler Frontotemporal Degener        ISSN: 2167-8421            Impact factor:   4.092


  6 in total

1.  Incidence, prevalence and disability associated with neurological disorders in Italy between 1990 and 2019: an analysis based on the Global Burden of Disease Study 2019.

Authors:  Alberto Raggi; Lorenzo Monasta; Ettore Beghi; Valeria Caso; Giulio Castelpietra; Stefania Mondello; Giorgia Giussani; Giancarlo Logroscino; Francesca Giulia Magnani; Marco Piccininni; Elisabetta Pupillo; Stefano Ricci; Luca Ronfani; Paola Santalucia; Davide Sattin; Silvia Schiavolin; Claudia Toppo; Eugenio Traini; Jaimie Steinmetz; Emma Nichols; Rui Ma; Theo Vos; Valery Feigin; Matilde Leonardi
Journal:  J Neurol       Date:  2021-09-08       Impact factor: 6.682

2.  Home-Based Adaptation to Night-Time Non-Invasive Ventilation in Patients with Amyotrophic Lateral Sclerosis: A Randomized Controlled Trial.

Authors:  Eleonora Volpato; Michele Vitacca; Luciana Ptacinsky; Agata Lax; Salvatore D'Ascenzo; Enrica Bertella; Mara Paneroni; Silvia Grilli; Paolo Banfi
Journal:  J Clin Med       Date:  2022-06-02       Impact factor: 4.964

3.  Critically appraised paper: In people with chronic obstructive pulmonary disease, initiation of nocturnal non-invasive ventilation at home is non-inferior to initiation during a hospital admission [commentary].

Authors:  Anne Holland
Journal:  J Physiother       Date:  2020-08-23       Impact factor: 7.000

4.  Transcutaneous carbon dioxide monitoring in ALS: Assessment of hypoventilation heats up.

Authors:  Jason Ackrivo; Andrew Geronimo
Journal:  Muscle Nerve       Date:  2022-02-14       Impact factor: 3.217

5.  REINVENT: ERS International survey on REstrictive thoracic diseases IN long term home noninvasive VENTilation.

Authors:  Paola Pierucci; Claudia Crimi; Annalisa Carlucci; Giovanna E Carpagnano; Jean-Paul Janssens; Manel Lujan; Alberto Noto; Peter J Wijkstra; Wolfram Windisch; Raffaele Scala
Journal:  ERJ Open Res       Date:  2021-04-19

6.  The Global Burden of Motor Neuron Disease: An Analysis of the 2019 Global Burden of Disease Study.

Authors:  Jin Park; Jee-Eun Kim; Tae-Jin Song
Journal:  Front Neurol       Date:  2022-04-21       Impact factor: 4.003

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.